ArticleFrontiers in oncology2026
MUC21 is downregulated in oral squamous cell carcinoma and associated with poor prognosis.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although mucins are generally linked to aggressive tumor behavior and poor clinical outcomes, the role of MUC21 in oral squamous cell carcinoma (OSCC) remains unexplored. Previous Methods: We analyzed microarray data from 10 OSCC tissues and paired adjacent normal tissues (para-OSCC), along with GEO and TCGA RNA-seq datasets, to identify differentially expressed genes, including MUC21. qRT-PCR was performed to validate MUC21 expression and its co-expressed epithelial differentiation-related genes. Additionally, immunohistochemistry (IHC) on 102 paired OSCC/para-OSCC samples assessed the correlation between MUC21 expression and clinical outcomes. Results: MUC21 was significantly downregulated in OSCC compared to normal tissue, supported by high-throughput datasets, qRT-PCR, and IHC. We identified 11 co-expressed genes, including epithelial differentiation markers (KRT4, KRT13, CRNN), which were further validated. Low MUC21 expression correlated with pathological lymph node metastasis, poor tumor differentiation, and reduced survival. Furthermore, MUC21 Knockdown significantly increased cell proliferation, migration and invasion in OSCC cell lines and vice versa. Conclusion: MUC21 downregulation is associated with reduced epithelial differentiation, increased clinical aggressiveness, and worse prognosis in OSCC. MUC21 may serve as a novel prognostic biomarker and tumor suppressor gene in OSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.